Dr. Michaela Liedtke, MD
Hematology (Hematology (Internal Medicine) Physician)
300 Pasteur Dr
Stanford, CA 94305
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 32
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 395
Licensed in California since 2004, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
CA license A86006 (first issued 2004; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Stanford Health Care Stanford, CA
- Renown Regional Medical Center Reno, NV
- Stanford Health Care Tri-Valley Pleasanton, CA
Medical groups
- Stanford Health Care (3,122 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 395
- Services billed
- 905
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 332 | 166 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 304 | 62 |
| Established patient office or other outpatient visit, 30-39 minutes | 223 | 156 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 47 | 40 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 42 | 27 |
| New patient office or other outpatient visit, 60-74 minutes | 40 | 40 |
| Established patient office or other outpatient visit, 20-29 minutes | 39 | 37 |
| Hospital discharge day management, more than 30 minutes | 38 | 33 |
| Hospital discharge day management, 30 minutes or less | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Stanford, CA | 78 |
| Venclexta (venetoclax) | 42 |
| Pomalyst (pomalidomide) | 40 |
| Revlimid (lenalidomide) | 33 |
| Dexamethasone Other prescribers in Stanford, CA | 31 |
| Entecavir | 12 |
| Gabapentin Other prescribers in Stanford, CA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 5 payments worth $8,454 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $2,865 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $2,858 |
| AstraZeneca UK Limited | $2,460 |
| Taiho Oncology, Inc. | $272 |
| Consulting Fee | $7,775 |
|---|---|
| Speaking at a medical education program | $679 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Aug 22, 2025 | Consulting Fee | $2,865 |
| AstraZeneca UK Limited Jun 3, 2025 | Consulting Fee | $2,460 |
| AstraZeneca Pharmaceuticals LP Aug 1, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $2,450 |
| AstraZeneca Pharmaceuticals LP Oct 31, 2025 | Speaking at a medical education program | $408 |
| Taiho Oncology, Inc. Oct 31, 2025 | Speaking at a medical education program | $272 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $202,480 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia in Treatment Naive Patients with Stage IIIa AL Ca…
Alexion Pharmaceuticals, Inc. - A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia
AstraZeneca Pharmaceuticals LP - Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Celgene Corporation · Recruiting · NCT03435796 - A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
AbbVie Inc. · Active, not recruiting · NCT05308654 - A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients with Stage IIIb AL Cardi…
Alexion Pharmaceuticals, Inc. - Phase 3, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in relapsed or refractory multiple myeloma
Celgene Corporation - A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amylo…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.